472 filings
Page 5 of 24
EFFECT
5gvaqafq
8 Jul 21
Notice of effectiveness
12:15am
424B3
vd2jg 36m
7 Jul 21
Prospectus supplement
5:16pm
DEFA14A
a08scd5 ofaq06
2 Jul 21
Additional proxy soliciting materials
7:06am
CORRESP
qj3cgj mz
2 Jul 21
Correspondence with SEC
12:00am
UPLOAD
up6vne 72w
1 Jul 21
Letter from SEC
12:00am
8-K
tr0yd 1ved
8 Jun 21
Regulation FD Disclosure
2:01pm
8-K
e6bi nk6e2bb
25 May 21
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer
9:00am
8-K
cjb74ud10 3m
20 May 21
NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
9:00am
8-K
x8kg96p5pjum278af gd
13 May 21
NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021
4:32pm
8-K
3x23624v
12 May 21
NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors
4:30pm
8-K
5jkqfaqhpewbkxkvyfa
30 Apr 21
Other Events
5:01pm
8-K
d1y65uor9
27 Apr 21
Entry into a Material Definitive Agreement
7:30am
8-K
eiwtv 6iwj2xl4f6ylo
26 Apr 21
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:11pm
424B5
eej8s9aaw9e4i
23 Apr 21
Prospectus supplement for primary offering
4:05pm
8-K
6k3j4e ft01m0ejs9k
22 Apr 21
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
9:33am
424B5
bxunrbu3t01jd8h9q
21 Apr 21
Prospectus supplement for primary offering
4:03pm
EFFECT
ncb4y051a3we ja
15 Apr 21
Notice of effectiveness
12:15am